Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Dec 6;14(23):1962. doi: 10.3390/nano14231962

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2024 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Neuroprotective effects of MPEG-2000-DSPE-edaravone (MDE) on Parkinson’s disease cell model. A cell model of Parkinson’s disease was established in PC12 cells through exposure to rotenone (1 μM), and the reversible effects of MDE and edaravone were investigated. PC12 cells were divided into four groups: blank group (no treatment), rotenone group (1 μM rotenone), rotenone + MDE group (1 μM rotenone and 12.5 μg/mL MDE), and rotenone + EDR group (1 μM rotenone and edaravone solution). (A) Cell cycle determined via flow cytometry. (B) Cell apoptosis determined via flow cytometry. (C) Cell migration determined via wound healing assay. Each experiment was repeated at least six times. Scale bars are 200 μm.